Unregistered Sales of Equity Securities

Business Context and Reporting Period

Company: Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP)

Filing Type: Form 8-K (Current Report)

Report Date: June 14, 2024 (Events reported through June 20, 2024)

Context: The filing reports a private placement of Series A Preferred Stock, the grant of CEO stock options, and the issuance of a press release regarding the financing closing.

Key Financial Metrics and Capital Structure

Capital Raised: $4.3 million in gross proceeds.

Instrument: 4,300 shares of Series A Preferred Stock sold at $1,000 per share.

Payment Method: Combination of cash and short-term collateralized promissory notes.

Additional Equity Interest: Investors received a 6.45% non-voting equity ownership interest in two newly formed subsidiaries: SNAP Biosciences Inc. and GEAR Therapeutics Inc.

CEO Compensation Grant: 2,400,000 fully vested stock options granted to CEO David Mehalick with a 10-year term.

Financial Statements: The filing text does not provide specific values for revenue, profit, cash flow, margins, or total debt.

Material Changes and Transaction Terms

  • Series A Preferred Stock Terms:
    • Conversion: Initial conversion price of $0.40 per share of common stock. Automatic conversion triggers upon a fundraising transaction raising at least $20 million in gross proceeds.
    • Rank: Senior to common stock and other classes not senior or pari passu.
    • Dividends: Paid on an "as-if-converted" basis when common stock dividends are paid.
    • Liquidation Preference: Holders receive the greater of the Stated Value ($1,000) plus accrued dividends or the amount payable if converted immediately prior to liquidation.
    • Voting: Voted on an "as converted" basis.
  • Limitations: Conversion and dividend rights are subject to beneficial ownership limitations (20% threshold) and Nasdaq market limitations (19.99% of outstanding common stock).

Guidance, Outlook, and Risks

Outlook: The filing does not contain specific financial guidance or forward-looking projections regarding revenue or clinical milestones.

Risks and Contingencies:

  • Conversion Restrictions: The ability of investors to convert preferred stock into common stock is restricted by beneficial ownership caps and Nasdaq listing rules regarding share issuance limits.
  • Automatic Conversion Trigger: The preferred stock will automatically convert if the company raises $20 million or more in a future fundraising transaction.

Investor Verification Checklist

  • Verify the exact split of proceeds between cash and short-term collateralized promissory notes.
  • Confirm the current outstanding share count of common stock to assess the potential dilution impact of the Series A Preferred Stock conversion at $0.40 per share.
  • Review the terms of the short-term collateralized promissory notes for interest rates and maturity dates.
  • Assess the impact of the 2,400,000 CEO stock options on future dilution and cash flow if exercised.
  • Examine the financial health and strategic role of the newly formed subsidiaries (SNAP Biosciences Inc. and GEAR Therapeutics Inc.) regarding the 6.45% investor stake.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.